NR-565 ADVANCED
PHARMACOLOGY
FUNDAMENTALS –
MIDTERM EXAM
Section 1: Pharmacokinetics & Pharmacodynamics
1. A nurse practitioner is explaining the drug development process to a patient.
Which phase of drug development focuses on determining safety, dosing, and
adverse effects in a small group of healthy volunteers?
A. Preclinical stage
B. Phase 1 clinical trials
C. Phase 2 clinical trials
D. Phase 3 clinical trials
Rationale: Phase 1 trials involve a small number (20–100) of healthy volunteers to
evaluate drug safety, determine a safe dosage range, identify side effects, and study
pharmacokinetics. Preclinical trials involve animal testing. Phase 2 trials test efficacy in a
small patient population. Phase 3 trials involve larger patient groups to confirm
effectiveness and monitor side effects.
,2. Pharmacodynamics is best defined as:
A. What the body does to the drug
B. What the drug does to the body
C. The study of drug absorption
D. The study of drug excretion
Rationale: Pharmacodynamics describes the biochemical and physiologic effects of
drugs on the body, including receptor binding, post-receptor effects, and clinical
response. Pharmacokinetics describes what the body does to the drug (absorption,
distribution, metabolism, excretion).
3. Pharmacokinetics is best defined as:
A. The study of drug movement throughout the body
B. What the drug does to the body
C. The study of receptor binding
D. The study of signal transduction
Rationale: Pharmacokinetics is the study of drug movement throughout the body,
including absorption, distribution, metabolism, and excretion (ADME). It describes "what
the body does to the drug".
4. A patient with hypoalbuminemia is prescribed a highly protein-bound
medication. The NP should anticipate which effect?
A. Decreased free drug concentration
B. Increased free drug concentration with potential toxicity
C. No change in drug activity
D. Decreased drug clearance
Rationale: A low albumin level reduces protein binding sites. For drugs that are
normally highly protein-bound, this results in a higher fraction of free (active) drug in
the circulation, leading to increased drug effect and toxicity at standard doses.
,5. The NP prescribes a medication that undergoes significant first-pass
metabolism. To avoid this effect, which route should the NP choose?
A. Oral
B. Sublingual or IV
C. Rectal
D. Intramuscular
Rationale: Sublingual and IV routes bypass the hepatic portal system, allowing the drug
to reach systemic circulation before passing through the liver. Drugs with extensive first-
pass metabolism (e.g., nitroglycerin) are often given via these routes.
6. A patient with chronic kidney disease stage 4 requires a medication primarily
eliminated by the kidneys. What is the most appropriate dosing adjustment?
A. Increase the dose
B. Decrease the dose or increase the dosing interval
C. No change needed
D. Administer the medication intravenously
Rationale: In CKD, impaired renal elimination leads to drug accumulation and toxicity
risk. Dose reduction or extended dosing intervals maintain therapeutic levels without
toxicity. Creatinine clearance or GFR should be calculated to guide adjustment.
7. A drug with a narrow therapeutic index requires close monitoring because:
A. It is effective at very low doses
B. The difference between therapeutic and toxic doses is small
C. It has a long half-life
D. It is metabolized by multiple pathways
, Rationale: Drugs with a narrow therapeutic index (e.g., warfarin, digoxin, lithium,
phenytoin) have a small margin of safety between effective and toxic doses, requiring
therapeutic drug monitoring.
8. When prescribing a medication with a narrow therapeutic index (NTI), what
monitoring protocol is required?
A. Checking systemic blood counts once every five years
B. Ordering scheduled therapeutic drug monitoring (TDM) to measure serum peak
and trough levels
C. Relying entirely on the patient's subjective reports
D. Interchanging generic brands arbitrarily
Rationale: NTI drugs have a minimal margin between effective and toxic concentrations,
necessitating routine blood level tracking to guide dosage adjustments safely.
9. A nurse practitioner is evaluating the bioavailability of a new oral drug
formulation. The drug exhibits a profound "first-pass effect" during absorption.
Through which physiological pathway does this effect occur?
A. Excretion via the lungs during exhalation cycles
B. Absorption across the gastrointestinal tract into the portal vein system, leading
to immediate degradation by the liver before entering systemic circulation
C. Direct filtration by the glomerulus before any systemic distribution
D. Intracellular storage within skeletal muscle fibers
Rationale: The first-pass effect is the rapid hepatic metabolism of an orally
administered drug before it reaches systemic circulation, significantly reducing its
bioavailability.
10. A patient is prescribed a prodrug to manage a chronic cardiovascular
condition. The nurse practitioner must evaluate if the patient is a genetic "poor
PHARMACOLOGY
FUNDAMENTALS –
MIDTERM EXAM
Section 1: Pharmacokinetics & Pharmacodynamics
1. A nurse practitioner is explaining the drug development process to a patient.
Which phase of drug development focuses on determining safety, dosing, and
adverse effects in a small group of healthy volunteers?
A. Preclinical stage
B. Phase 1 clinical trials
C. Phase 2 clinical trials
D. Phase 3 clinical trials
Rationale: Phase 1 trials involve a small number (20–100) of healthy volunteers to
evaluate drug safety, determine a safe dosage range, identify side effects, and study
pharmacokinetics. Preclinical trials involve animal testing. Phase 2 trials test efficacy in a
small patient population. Phase 3 trials involve larger patient groups to confirm
effectiveness and monitor side effects.
,2. Pharmacodynamics is best defined as:
A. What the body does to the drug
B. What the drug does to the body
C. The study of drug absorption
D. The study of drug excretion
Rationale: Pharmacodynamics describes the biochemical and physiologic effects of
drugs on the body, including receptor binding, post-receptor effects, and clinical
response. Pharmacokinetics describes what the body does to the drug (absorption,
distribution, metabolism, excretion).
3. Pharmacokinetics is best defined as:
A. The study of drug movement throughout the body
B. What the drug does to the body
C. The study of receptor binding
D. The study of signal transduction
Rationale: Pharmacokinetics is the study of drug movement throughout the body,
including absorption, distribution, metabolism, and excretion (ADME). It describes "what
the body does to the drug".
4. A patient with hypoalbuminemia is prescribed a highly protein-bound
medication. The NP should anticipate which effect?
A. Decreased free drug concentration
B. Increased free drug concentration with potential toxicity
C. No change in drug activity
D. Decreased drug clearance
Rationale: A low albumin level reduces protein binding sites. For drugs that are
normally highly protein-bound, this results in a higher fraction of free (active) drug in
the circulation, leading to increased drug effect and toxicity at standard doses.
,5. The NP prescribes a medication that undergoes significant first-pass
metabolism. To avoid this effect, which route should the NP choose?
A. Oral
B. Sublingual or IV
C. Rectal
D. Intramuscular
Rationale: Sublingual and IV routes bypass the hepatic portal system, allowing the drug
to reach systemic circulation before passing through the liver. Drugs with extensive first-
pass metabolism (e.g., nitroglycerin) are often given via these routes.
6. A patient with chronic kidney disease stage 4 requires a medication primarily
eliminated by the kidneys. What is the most appropriate dosing adjustment?
A. Increase the dose
B. Decrease the dose or increase the dosing interval
C. No change needed
D. Administer the medication intravenously
Rationale: In CKD, impaired renal elimination leads to drug accumulation and toxicity
risk. Dose reduction or extended dosing intervals maintain therapeutic levels without
toxicity. Creatinine clearance or GFR should be calculated to guide adjustment.
7. A drug with a narrow therapeutic index requires close monitoring because:
A. It is effective at very low doses
B. The difference between therapeutic and toxic doses is small
C. It has a long half-life
D. It is metabolized by multiple pathways
, Rationale: Drugs with a narrow therapeutic index (e.g., warfarin, digoxin, lithium,
phenytoin) have a small margin of safety between effective and toxic doses, requiring
therapeutic drug monitoring.
8. When prescribing a medication with a narrow therapeutic index (NTI), what
monitoring protocol is required?
A. Checking systemic blood counts once every five years
B. Ordering scheduled therapeutic drug monitoring (TDM) to measure serum peak
and trough levels
C. Relying entirely on the patient's subjective reports
D. Interchanging generic brands arbitrarily
Rationale: NTI drugs have a minimal margin between effective and toxic concentrations,
necessitating routine blood level tracking to guide dosage adjustments safely.
9. A nurse practitioner is evaluating the bioavailability of a new oral drug
formulation. The drug exhibits a profound "first-pass effect" during absorption.
Through which physiological pathway does this effect occur?
A. Excretion via the lungs during exhalation cycles
B. Absorption across the gastrointestinal tract into the portal vein system, leading
to immediate degradation by the liver before entering systemic circulation
C. Direct filtration by the glomerulus before any systemic distribution
D. Intracellular storage within skeletal muscle fibers
Rationale: The first-pass effect is the rapid hepatic metabolism of an orally
administered drug before it reaches systemic circulation, significantly reducing its
bioavailability.
10. A patient is prescribed a prodrug to manage a chronic cardiovascular
condition. The nurse practitioner must evaluate if the patient is a genetic "poor
